Exact Sciences Corporation (NASDAQ:EXAS) posted its quarterly earnings results on Monday. The medical research company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.07, Briefing.com reports. The business had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The company’s revenue was up 158.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.36) earnings per share.

Shares of Exact Sciences Corporation (EXAS) traded down 2.07% during midday trading on Monday, hitting $50.10. 2,946,094 shares of the stock traded hands. The company’s 50 day moving average price is $46.51 and its 200-day moving average price is $37.94. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $51.70. The stock’s market cap is $5.97 billion.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/30/exact-sciences-corporation-exas-issues-quarterly-earnings-results-beats-expectations-by-0-07-eps.html.

In other news, SVP D Scott Coward sold 29,115 shares of Exact Sciences Corporation stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the transaction, the senior vice president now owns 64,991 shares in the company, valued at approximately $3,064,975.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Thomas D. Carey purchased 2,500 shares of Exact Sciences Corporation stock in a transaction dated Thursday, August 17th. The shares were bought at an average price of $37.71 per share, for a total transaction of $94,275.00. Following the acquisition, the director now owns 60,858 shares in the company, valued at $2,294,955.18. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 231,598 shares of company stock worth $10,182,030. Insiders own 4.00% of the company’s stock.

A number of equities analysts have weighed in on EXAS shares. Leerink Swann set a $45.00 price target on shares of Exact Sciences Corporation and gave the stock a “buy” rating in a research report on Thursday, August 24th. Robert W. Baird reissued a “buy” rating and issued a $49.00 target price on shares of Exact Sciences Corporation in a report on Friday, October 6th. Bank of America Corporation set a $56.00 target price on shares of Exact Sciences Corporation and gave the stock a “buy” rating in a report on Thursday, October 19th. Zacks Investment Research raised shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 target price on the stock in a report on Tuesday, September 26th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $60.00 target price (up previously from $45.00) on shares of Exact Sciences Corporation in a report on Tuesday, October 3rd. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $44.91.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.